Development of new drug deliverty system with liposome consist of comparable to the lipid composition of oral cancer cancer cell membrane
Development of new drug deliverty system with liposome consist of comparable to the lipid composition of oral cancer cancer cell membrane
批准号:
08672311
负责人:
TORATANI Shigeaki
金额:
$1.47万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1997
中文摘要
很早以前就知道,抗癌药物的疗效取决于靶癌细胞的组织类型。我们用无血清培养法检测了5株人癌细胞对顺铂、阿霉素和培普霉素的敏感性。在所测试的细胞系中,体外培养的滑腺腺癌细胞系(SAC)对顺铂的敏感性普遍高于鳞状细胞癌细胞系(SCC),而SCC对顺铂的耐药性相对较高。另一方面,SCC对阿霉素和培普霉素的敏感性高于SAC。已知顺铂、培普霉素和阿霉素是通过被动转运系统在细胞内摄取的。我们推测,这些抗癌药物作用的异质性与细胞内药物水平有关,这是由于癌细胞膜通透性的差异造成的。在无血清培养条件下,我们研究了细胞膜的脂质组成,从而确定了细胞膜的…更多的允许性。我们发现鳞状细胞癌中总膜脂的70%是磷脂,其余的是游离胆固醇。另一方面,SAC中80%的膜脂为甘油三酯和酯化胆固醇等中性脂类,20%为磷脂。与SCC相比,SAC较高的中性脂质水平可能会导致细胞膜流动性下降,这与顺铂的蓄积量较高是一致的。另一方面,阿霉素和培普霉素对SCC表现出较高的细胞毒性,其膜脂主要由磷脂组成,膜流动性高于SAC。因此,我们设计了与鳞状细胞癌细胞膜脂质组成相匹配的脂质体,构建了脂质体包裹顺铂,并在无血清培养中通过生长实验检测了SCC和SAC对脂质体包裹的顺铂的敏感性。结果表明,与单独使用顺铂或顺铂-脂质体混合物相比,脂质体包裹的顺铂对SCC的细胞毒作用增强。我们发现表皮生长因子受体(EGFR)在SCC和SAC上过表达,然后制备了针对EGFR的单抗(12-93),并用亲和素-生物素方法将脂质体包裹的顺铂与抗EGFR的单抗结合在一起。我们在体外检测了脂质体与抗鳞状细胞癌和囊状细胞癌的抗EGFR单抗的敏感性。与脂质体包裹的顺铂相比,该脂质体对SCC和SAC的细胞毒性有增强的趋势。较少
英文摘要
It has long been known that the effect of anti-cancer drug is dependent on the histological type of the target cancer cells. We have examined the sensitivity to cisplatin, doxorubicin and peplomycin of five human cancer cell lines by growth assay in serum-free culture. Of the cell line tested, slivary gland adenocarcinoma cell lines (SAC) were shown to be generally more sensitive to cisplatin than squmous cell carcinoma cell lines (SCC) in vitro, and SCC were relatively resistant to cisplatin. On the other hand, SCC were more sensitive to doxorubicin and peplomycin in comparison to SAC.It is known that cisplatin, peplomycin and doxorubicin were uptake in the cells by passive transport system. We have speculated that heterogeneity of these anticancer drug effects is correlated with intracellular drug level, resulted from the difference of membrane permiability of cancer cells. We studied the membrane lipid composition of the cell lines in serum-free medium, which determine the membrane … More permiability. We have found that 70% of total membrane lipid in SCC is phosholipid and remainder is free cholesterol. On the other hand, 80% of total membrane lipid in SAC in neutral lipid such as triglyceride and esterified cholesterol, and 20% is phospholipid. The higher neutral lipid level of SAC which should have resulted in decreased membrane fluidity, is consistent with the higher accumulation of cisplatin compared to SCC.On the other hand, doxorubicin and peplomycin exhibited high cytotoxicity to SCC,which membrane lipid consisted of phospholipid mainly and the membrane fluidity was higher than that of SAC.These result suggest that the lipid composition of cancer cell membranes is major factor determining the sensitivity of cancer cells to cisplatin, peplomycin and doxorubicin. Thus, we have designed liposome which is comparable to the lipid composition of SCC cell membrane, constructed the liposome-entrapped cisplatin and examined sensitivity to the liposome-entrapped cisplatin of both SCC and SAC by growth assay in serum-free culture. As the reult, the liposome-entrapped cisplatin exhibited enhanced cytotoxicity on SCC compare to either cisplatin alone or cisplatin-liposome mixture. And we have shown that epidermal growth factor receptor (EGFR) was over-expression on SCC and SAC.Then we made monoclonal antibody (12-93) to EGFR and combined liposome-entrapped cisplatin with anti-EGFR monoclonal antibody with avidin-biotin method. We have examined sensitivity to the liposome united with anti-EGFR monoclonal antibody of both SCC and SAC in vitro. This liposome had a tendency to enhance cytotoxicity on SCC and SAC compare to liposome-entrapped cisplatin. Less
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
虎谷 茂昭: "口腔癌細胞の膜脂質組成の相違に基づく抗癌剤感受性" Tiss. Cult. Res. Commun.15. 147-153 (1996)
Shigeaki Toratani:“基于口腔癌细胞膜脂质成分差异的抗癌药物敏感性”Res. Commun.147-153 (1996)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
虎谷 茂昭: "癌細胞膜の脂質組成の差を利用した癌化学療法の基礎的研究" 日本癌治療学会誌. 31・7. 413-419 (1996)
Shigeaki Toratani:“利用癌细胞膜脂质组成的差异进行癌症化疗的基础研究”日本癌症治疗学会杂志31・7(1996)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
S.Toratani, T.Okamoto, T.Shinki, T.Osaki, M.Yabumoto, R.Tanaka, R.Tani and K.Takada: "Sensitivities of Oral Cancer Cells to Various anti-Cancer Drugs based on the Difference of the Membrane Lipid Composition." Tiss.Cult.Res.Commun.15. 147-153 (1996)
S.Toratani、T.Okamoto、T.Shinki、T.Osaki、M.Yabumoto、R.Tanaka、R.Tani 和 K.Takada:“基于口腔癌细胞对各种抗癌药物的敏感性的差异
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
虎谷茂昭: "口腔癌細胞の膜脂質組成の相違に基づく抗癌剤感受性" Tiss. Cult. Res. Commun.15. 147-153 (1996)
Shigeaki Toratani:“基于口腔癌细胞膜脂质成分差异的抗癌药物敏感性”Res. Commun.147-153 (1996)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
S.Toratani, T.Okamoto, T.Osaki, T.Shinki and K.Takada: "A Study of Cancer Chemotherapy Based on the Difference in Lipid Composition of Cancer Cell Membrane." J.Jpn.Soc.Cancer Ther.31. 413-419 (1996)
S.Toratani、T.Okamoto、T.Osaki、T.Shinki 和 K.Takada:“基于癌细胞膜脂质成分差异的癌症化疗研究”。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 7 条
Proteomic analysis of molecular-targeted therapy against KGFR of salivary gland carcinomas
-
批准号:18592184
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.52万
-
财政年份:2006
-
负责人:TORATANI Shigeaki
-
依托单位:
Development of targeting therapy using specific difference of lipid composition of oral cancer cell, resistant
-
批准号:13672098
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.62万
-
财政年份:2001
-
负责人:TORATANI Shigeaki
-
依托单位:
Development of photodynamic therapy to early stage oral cancer using drug delivery system
-
批准号:11470438
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$3.78万
-
财政年份:1999
-
负责人:TORATANI Shigeaki
-
依托单位:
New targeting therapy with complex of liposome, consist of comparable lipid composition of oral cancer cells, and anti-EGF receptor antibody.
-
批准号:10557191
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$3.78万
-
财政年份:1998
-
负责人:TORATANI Shigeaki
-
依托单位: